Champions Oncology Inc
CSBR7.220USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
99.55MMarket Cap
33.44P/E TTM
More Details of Champions Oncology Inc Company
Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
Champions Oncology Inc Info
Ticker SymbolCSBR
Company nameChampions Oncology Inc
IPO dateNov 30, 1988
CEOBrainin (Robert)
Number of employees213
Security typeOrdinary Share
Fiscal year-endNov 30
AddressOne University Plaza,
CityHACKENSACK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07601
Phone12018088400
Websitehttps://championsoncology.com
Ticker SymbolCSBR
IPO dateNov 30, 1988
CEOBrainin (Robert)
Company Executives of Champions Oncology Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joel Ackerman
Mr. Joel Ackerman
Independent Director
Independent Director
1.06M
+9.81%
Dr. Ronnie Morris, M.D.
Dr. Ronnie Morris, M.D.
Chairman of the Board
Chairman of the Board
858.88K
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Director
Independent Director
767.04K
--
Mr. Scott R. Tobin
Mr. Scott R. Tobin
Independent Director
Independent Director
53.40K
+77.99%
Dr. Philip Breitfeld, M.D.
Dr. Philip Breitfeld, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel N. (Dan) Mendelson
Mr. Daniel N. (Dan) Mendelson
Independent Director
Independent Director
--
--
Mr. David Miller, CPA
Mr. David Miller, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Robert (Rob) Brainin
Mr. Robert (Rob) Brainin
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joel Ackerman
Mr. Joel Ackerman
Independent Director
Independent Director
1.06M
+9.81%
Dr. Ronnie Morris, M.D.
Dr. Ronnie Morris, M.D.
Chairman of the Board
Chairman of the Board
858.88K
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Director
Independent Director
767.04K
--
Mr. Scott R. Tobin
Mr. Scott R. Tobin
Independent Director
Independent Director
53.40K
+77.99%
Dr. Philip Breitfeld, M.D.
Dr. Philip Breitfeld, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel N. (Dan) Mendelson
Mr. Daniel N. (Dan) Mendelson
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2026Q1
FY2025
FY2025Q3
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
13.99M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Battery Management Corp
17.44%
New Enterprise Associates (NEA)
12.34%
Ackerman (Joel)
7.61%
West Elk Capital, LLC
6.36%
Morris (Ronnie)
6.19%
Other
50.07%
Shareholders
Shareholders
Proportion
Battery Management Corp
17.44%
New Enterprise Associates (NEA)
12.34%
Ackerman (Joel)
7.61%
West Elk Capital, LLC
6.36%
Morris (Ronnie)
6.19%
Other
50.07%
Shareholder Types
Shareholders
Proportion
Individual Investor
26.67%
Investment Advisor
23.00%
Venture Capital
12.34%
Hedge Fund
7.84%
Investment Advisor/Hedge Fund
3.88%
Research Firm
0.20%
Other
26.06%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
61
6.56M
52.08%
--
2025Q3
62
6.56M
52.44%
-79.02K
2025Q2
63
6.67M
52.80%
-161.89K
2025Q1
63
6.82M
51.27%
-269.97K
2024Q4
54
6.61M
53.30%
-64.85K
2024Q3
52
6.72M
54.61%
-200.66K
2024Q2
56
5.89M
46.40%
+140.55K
2024Q1
56
5.75M
45.40%
-421.54K
2023Q4
54
5.73M
45.75%
-128.46K
2023Q3
60
6.95M
52.42%
-72.37K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Battery Management Corp
2.40M
17.39%
-23.97K
-0.99%
Aug 22, 2025
New Enterprise Associates (NEA)
1.71M
12.43%
--
--
Jun 30, 2025
Ackerman (Joel)
962.13K
6.98%
--
--
Aug 22, 2025
West Elk Capital, LLC
882.58K
6.4%
-210.81K
-19.28%
Sep 30, 2024
Morris (Ronnie)
858.88K
6.23%
--
--
Aug 22, 2025
Sidransky (David)
767.04K
5.56%
--
--
Aug 22, 2025
Pessin (Norman H)
742.16K
5.38%
--
--
Aug 22, 2025
The Vanguard Group, Inc.
327.03K
2.37%
+19.16K
+6.22%
Jun 30, 2025
Tocqueville Asset Management LP
399.88K
2.9%
--
--
Jun 30, 2025
Mendelson (Daniel Newman)
198.63K
1.44%
--
--
Aug 22, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Champions Oncology Inc?
The top five shareholders of Champions Oncology Inc are:
Battery Management Corp holds 2.40M shares, accounting for 17.39% of the total shares.
New Enterprise Associates (NEA) holds 1.71M shares, accounting for 12.43% of the total shares.
Ackerman (Joel) holds 962.13K shares, accounting for 6.98% of the total shares.
West Elk Capital, LLC holds 882.58K shares, accounting for 6.40% of the total shares.
Morris (Ronnie) holds 858.88K shares, accounting for 6.23% of the total shares.
Battery Management Corp holds 2.40M shares, accounting for 17.39% of the total shares.
New Enterprise Associates (NEA) holds 1.71M shares, accounting for 12.43% of the total shares.
Ackerman (Joel) holds 962.13K shares, accounting for 6.98% of the total shares.
West Elk Capital, LLC holds 882.58K shares, accounting for 6.40% of the total shares.
Morris (Ronnie) holds 858.88K shares, accounting for 6.23% of the total shares.
What are the top three shareholder types of Champions Oncology Inc?
The top three shareholder types of Champions Oncology Inc are:
Battery Management Corp
New Enterprise Associates (NEA)
Ackerman (Joel)
Battery Management Corp
New Enterprise Associates (NEA)
Ackerman (Joel)
How many institutions hold shares of Champions Oncology Inc (CSBR)?
As of 2025Q4, 61 institutions hold shares of Champions Oncology Inc, with a combined market value of approximately 6.56M, accounting for 52.08% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.35%.
What is the biggest source of revenue for Champions Oncology Inc?
In FY2026Q1, the -- business generated the highest revenue for Champions Oncology Inc, amounting to -- and accounting for --% of total revenue.
